<?xml version="1.0" encoding="iso-8859-1" ?>
<rss version="2.0" xmlns:s="http://resources.bnet.com/">
<channel>
	<title><![CDATA[licensing agreement and merck Resources | BNET]]></title>
	<link><![CDATA[http://resources.bnet.com/topic/licensing+agreement+and+merck.html]]></link>
	<description><![CDATA[White papers, case studies, business articles, and blog posts relating to licensing agreement and merck]]></description>
	<s:counts start="0" returned="19" found="19" />
	<language>en-us</language>
	<item>
		<title><![CDATA[Merck Deal Provides Nice Upside for DepoMed]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F150556-merck-deal-provides-nice-upside-for-depomed%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Zacks.com submits:   This morning, DepoMed DEPO announced it has signed a non-exclusive licensing agreement with Merck MRK, whereby Merck will have access to the company's technology for extended release metformin.  We expect that Merck is seeking to co-formulate DepoMed's metformin XR candidate with its DPP-IV agent, Januvia...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Wed, 22 Jul 2009 11:32:40 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/zacks.com.html"><![CDATA[Zacks.com]]></category>
		<category domain="http://resources.bnet.com/topic/depomed+inc..html"><![CDATA[DepoMed Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/merck+%2526+co.+inc..html"><![CDATA[Merck & Co. Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">DEPO</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MRK</category>
		<category domain="tickers">DEPO,MRK</category>
	</item>
	<item>
		<title><![CDATA[Cardiome May See More Upside When IV Formulation Is Clarified - RBC]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F130809-cardiome-may-see-more-upside-when-iv-formulation-is-clarified-rbc%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[FP Trading Desk submits:  Cardiome Pharma Corp. CRME shares were still on the rise Monday following last week's announcement of a significant licensing agreement with Merck & Co Inc. MRK. But according to RBC Capital Markets analyst Douglas Miehm, the response from shareholders may turn even more positive once...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Tue, 14 Apr 2009 01:34:30 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/fp+trading+desk.html"><![CDATA[FP Trading Desk]]></category>
		<category domain="http://resources.bnet.com/topic/merck+%2526+co.+inc..html"><![CDATA[Merck & Co. Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MRK</category>
		<category domain="tickers">MRK</category>
	</item>
	<item>
		<title><![CDATA[EMD Serono Snags US license for Tesamorelin From Theratechnologies]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F103241-emd-serono-snags-us-license-for-tesamorelin-from-theratechnologies%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Eben Tessari submits:   Theratechnologies and EMD Serono, US arm of Merck KGaA (MKGAY.PK), announced they have entered into a collaboration and licensing agreement for the exclusive commercialization rights to tesamorelin in the United States for the treatment of excess abdominal fat in HIV patients with lipodystrophy. Theratechnologies retains all...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Fri, 31 Oct 2008 03:44:29 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/commercialization.html"><![CDATA[Commercialization]]></category>
		<category domain="http://resources.bnet.com/topic/serono+s.a..html"><![CDATA[Serono S.A.]]></category>
		<category domain="http://resources.bnet.com/topic/hiv+virus.html"><![CDATA[HIV Virus]]></category>
		<category domain="http://resources.bnet.com/topic/seeking+alpha.html"><![CDATA[Seeking Alpha]]></category>
		<category domain="http://resources.bnet.com/topic/tesamorelin.html"><![CDATA[Tesamorelin]]></category>
		<category domain="http://resources.bnet.com/topic/eben+tessari.html"><![CDATA[Eben Tessari]]></category>
		<category domain="http://resources.bnet.com/topic/theratechnologies.html"><![CDATA[Theratechnologies]]></category>
		<category domain="http://resources.bnet.com/topic/service+management.html"><![CDATA[Service Management]]></category>
		<category domain="http://resources.bnet.com/topic/eben+tessari.html"><![CDATA[Eben Tessari]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
	</item>
	<item>
		<title><![CDATA[Merck Signs Licensing Agreement with Sol-Gel Technologies]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2008_Jan_31/ai_n24241441]]></link>
		<description><![CDATA[BET SHEMESH, Israel -- At the end of 2007 the Merck KGaA turned its existing exclusive contract with Sol-Gel Technologies Ltd. in Israel into a licensing agreement. This licensing agreement allows Merck, besides the exclusive rights to marketing and global sales, also the permission to manufacture Sol-Gel's UV-Pearls[TM]. Behind the...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Thu, 31 Jan 2008 00:00:00 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/licensing+agreement.html"><![CDATA[licensing agreement]]></category>
		<category domain="http://resources.bnet.com/topic/merck+%2526+co.+inc..html"><![CDATA[Merck & Co. Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MRK</category>
		<category domain="tickers">MRK</category>
	</item>
	<item>
		<title><![CDATA[Idera Pharmaceuticals and Merck KGaA to Collaborate on Development of TLR9 Agonists for Treatment of Cancer]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2007_Dec_19/ai_n27478874]]></link>
		<description><![CDATA[CAMBRIDGE, Mass. -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) announced today that it has entered into a worldwide licensing and collaboration agreement with Merck KGaA of Darmstadt, Germany, for the research, development and commercialization of Idera's Toll-like Receptor 9 (TLR9) agonists for the treatment of cancer.]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Wed, 19 Dec 2007 00:00:00 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/merck+%2526+co.+inc..html"><![CDATA[Merck & Co. Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MRK</category>
		<category domain="tickers">MRK</category>
	</item>
	<item>
		<title><![CDATA[Applera Corporation F1Q08 (Qtr End 9/30/07) Earnings Call Transcript]]></title>
		<link><![CDATA[http://www.bnet.com/2462-14046_23-232503.html]]></link>
		<description><![CDATA[ Question-and-Answer SessionOperator  Thank you sir. [Operator&#8217;s instructions.]  One moment while we compile a list of questions. Our first question will come from the line of Ross Muken of Deutsche Bank, please proceed.  Ross Muken &#8211; Deutsche Bank  Good morning everyone.  Mark P. Stevenson &#8211;...]]></description>
		<s:doctype><![CDATA[Earnings calls]]></s:doctype>
		<pubDate>Thu, 25 Oct 2007 22:00:10 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://resources.bnet.com/topic/applera+corp..html"><![CDATA[Applera Corp.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">ABI</category>
		<category domain="tickers">ABI</category>
	</item>
	<item>
		<title><![CDATA[Epitome Biosystems Initiates Second Partnership with EMD Chemicals for Commercial Products]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2007_July_10/ai_n27298758]]></link>
		<description><![CDATA[WALTHAM, Mass. -- Epitome Biosystems announced today a second licensing and development agreement with EMD Chemicals Inc., an affiliate of Merck KGaA of Germany, using Epitome's EpiTag([TM]) technology. The partnership will focus on developing EpiTag([TM]) assays for the quantitative measurement of various targets, including membrane proteins. Products will be manufactured,...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Tue, 10 Jul 2007 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biosystems.html"><![CDATA[Biosystems]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[Ingenuity Systems Announces Extension and Expansion of its Licensing Agreement with Merck.]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_hb5570/is_200702/ai_n23597717]]></link>
		<description><![CDATA[REDWOOD CITY, California, February 13 /PRNewswire/ --    REDWOOD CITY, California, February 13 /PRNewswire/ --  ]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Tue, 13 Feb 2007 00:00:00 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/licensing+agreement.html"><![CDATA[licensing agreement]]></category>
		<category domain="http://resources.bnet.com/topic/merck+%2526+co.+inc..html"><![CDATA[Merck & Co. Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MRK</category>
		<category domain="tickers">MRK</category>
	</item>
	<item>
		<title><![CDATA[Merck & Co., Inc. and Crucell Sign Cross-licensing Agreement on Vaccine Production Technology]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_pwwi/is_200612/ai_n17071323]]></link>
		<description><![CDATA[Dutch  biotechnology company Crucell N.V.  (Euronext, NASDAQ: CRXL;  Swiss Exchange: CRX) announced today that it has  signed a cross-licensing agreement with Merck &  Co.,  Inc. In  addition  to previously  licensed  rights to PER.C6, the  agreement  opens  the...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Wed, 27 Dec 2006 00:00:00 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/merck+%2526+co.+inc..html"><![CDATA[Merck & Co. Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/vaccine.html"><![CDATA[vaccine]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MRK</category>
		<category domain="tickers">MRK</category>
	</item>
	<item>
		<title><![CDATA[Materia Licenses Metathesis Catalyst Platform to Merck & Co., Inc]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2006_Dec_14/ai_n27086570]]></link>
		<description><![CDATA[PASADENA, Calif. -- Materia, Inc., a catalyst technology company, announced today the non-exclusive licensing of its metathesis platform to Merck & Co, Inc., a global pharmaceutical company, for use in the discovery and development of pharmaceuticals. No financial terms of the agreement were disclosed.]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Thu, 14 Dec 2006 00:00:00 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/merck+%2526+co.+inc..html"><![CDATA[Merck & Co. Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MRK</category>
		<category domain="tickers">MRK</category>
	</item>
	<item>
		<title><![CDATA[Ambrilia Biopharma and Merck & Co., Inc. Sign Licensing Agreement Granting Merck Worldwide Rights to Ambrilia's HIV/AIDS Protease Inhibitor Program]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_pwwi/is_200610/ai_n16779493]]></link>
		<description><![CDATA[Ambrilia Biopharma Inc. (TSX: AMB), a biopharmaceutical company developing innovative therapeutics in the fields of cancer and infectious diseases, and Merck & Co., Inc., one of the world's leading pharmaceutical companies, announced today that Ambrilia has entered into an exclusive licensing agreement granting Merck - through an affiliate - the...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Thu, 12 Oct 2006 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/licensing+agreement.html"><![CDATA[licensing agreement]]></category>
		<category domain="http://resources.bnet.com/topic/merck+%2526+co.+inc..html"><![CDATA[Merck & Co. Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MRK</category>
		<category domain="tickers">MRK</category>
	</item>
	<item>
		<title><![CDATA[Ambrilia Biopharma and Merck & Co., Inc. Sign Licensing Agreement Granting Merck Worldwide Rights to Ambrilia's HIV/AIDS Protease Inhibitor Program; Ambrilia to receive an upfront payment of $US 17 million and potential milestones of up to $US 215 mil]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_hb5559/is_200610/ai_n22530983]]></link>
		<description><![CDATA[MONTREAL, CANADA and WHITEHOUSE STATION, NEW JERSEY, Oct 12, 2006  CCNMatthews via COMTEX -- Ambrilia Biopharma Inc. (TSX:AMB), a  biopharmaceutical company developing innovative therapeutics in the  fields of cancer and infectious diseases, and Merck  MONTREAL, CANADA and WHITEHOUSE STATION, NEW JERSEY, Oct 12, 2006  (CCNMatthews...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Thu, 12 Oct 2006 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/merck+%2526+co.+inc..html"><![CDATA[Merck & Co. Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/payment.html"><![CDATA[payment]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MRK</category>
		<category domain="tickers">MRK</category>
	</item>
	<item>
		<title><![CDATA[Ambrilia Biopharma and Merck & Co., Inc. Sign Licensing Agreement Granting Merck Worldwide Rights to Ambrilia's HIV/AIDS Protease Inhibitor Program]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2006_Oct_12/ai_n27040293]]></link>
		<description><![CDATA[Ambrilia to Receive an Upfront Payment of $US 17 Million and Potential Milestones of Up to $US 215 Million]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Thu, 12 Oct 2006 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/licensing+agreement.html"><![CDATA[licensing agreement]]></category>
		<category domain="http://resources.bnet.com/topic/merck+%2526+co.+inc..html"><![CDATA[Merck & Co. Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MRK</category>
		<category domain="tickers">MRK</category>
	</item>
	<item>
		<title><![CDATA[Sention to Develop Novel Merck Compounds for Mental Retardation, Sention Secures Access to Potential New Product]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2005_Jan_19/ai_n8700273]]></link>
		<description><![CDATA[PROVIDENCE, R.I. -- Sention Inc. today announced that it has entered into an exclusive licensing and research collaboration agreement with Merck & Co., Inc. (NYSE: MRK) to develop a family of Merck compounds known as mGluR5 antagonists as potential treatments for Fragile X mental retardation. Fragile X is the most...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Wed, 19 Jan 2005 00:00:00 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/merck+%2526+co.+inc..html"><![CDATA[Merck & Co. Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/microsoft+access.html"><![CDATA[Microsoft Access]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MRK</category>
		<category domain="tickers">MRK</category>
	</item>
	<item>
		<title><![CDATA[Monot Signs Agreement.(licenses Rucinol from Pola Cosmetics Inc.)(Brief Article)]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_hb4250/is_200102/ai_n13215501]]></link>
		<description><![CDATA[MONOT, the French arm of Merck KGaA's consumer healthcare  business, has signed a licensing agreement for the exclusive rights to  manufacture and sell products that contain skin lightener Rucinol in  Europe. Pola Chemicals of Tokyo, Japan, holds the patent for Rucinol.   ]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Mon, 26 Feb 2001 23:59:59 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/merck+%2526+co.+inc..html"><![CDATA[Merck & Co. Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/pola+cosmetics+inc..html"><![CDATA[Pola Cosmetics Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MRK</category>
		<category domain="tickers">MRK</category>
	</item>
	<item>
		<title><![CDATA[Merck Markets Folates.(Brief Article)]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_hb4250/is_200002/ai_n13202922]]></link>
		<description><![CDATA[AFTER SIGNING an exclusive licensing  agreement, Merck KGaA and the  South Alabama Medical Science Foundation have granted Merck's  cosmetic health and nutrition division the fights to market naturally  ...    AFTER SIGNING an exclusive licensing  agreement, Merck KGaA and the  South Alabama...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Mon, 07 Feb 2000 00:00:00 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/merck+%2526+co.+inc..html"><![CDATA[Merck & Co. Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MRK</category>
		<category domain="tickers">MRK</category>
	</item>
	<item>
		<title><![CDATA[Cytogen, DuPont Merck End Quadramet Agreement.(pain killer)(Brief Article)]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_hb045/is_199806/ai_n26471437]]></link>
		<description><![CDATA[Biopharmaceutical maker Cytogen says it has ended a licensing  agreement with DuPont Merck for Quadramet, a pain relief drug for bone  cancer patients. The companies recently settled a lawsuit brought by  Cytogen after DuPont Merck said it would stop marketing the drug (CW,  June 5, p....]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Wed, 17 Jun 1998 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/cytogen.html"><![CDATA[Cytogen]]></category>
		<category domain="http://resources.bnet.com/topic/e.i.+du+pont+de+nemours+%2526+co..html"><![CDATA[E.I. Du Pont de Nemours & Co.]]></category>
		<category domain="http://resources.bnet.com/topic/merck+%2526+co.+inc..html"><![CDATA[Merck & Co. Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MRK</category>
		<category domain="tickers">MRK</category>
	</item>
	<item>
		<title><![CDATA[Transcell and Merck Enter into Anti-Bacterial Research Collaboration]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_1997_July_7/ai_19563927]]></link>
		<description><![CDATA[PRINCETON, N.J.--BW HealthWire--July 7, 1997-- Transcell Technologies, Inc., a majority-owned subsidiary of Interneuron Pharmaceuticals, Inc. (NASDAQ:IPIC) and Interneuron today announced that they have entered into a collaborative research and licensing agreement with Merck & Co., Inc. (NYSE:MRK) to discover and commercialize novel antibacterial agents.]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Mon, 07 Jul 1997 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/merck+%2526+co.+inc..html"><![CDATA[Merck & Co. Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MRK</category>
		<category domain="tickers">MRK</category>
	</item>
	<item>
		<title><![CDATA[Merck enters research agreement with The University of Oxford and the Wellcome Trust; Unique Collaboration Targets Gene Identification and Treatment of Type I Diabetes]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_1996_May_29/ai_18333671]]></link>
		<description><![CDATA[WHITEHOUSE STATION, N.J., USA--BUSINESS WIRE-- May 29, 1996-- Merck & Co., Inc., today announced a collaborative research and licensing agreement with The Wellcome Trust and the University of Oxford for work to be completed at the Wellcome Trust Centre for Human Genetics at the University of Oxford for the discovery...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Wed, 29 May 1996 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/agreement.html"><![CDATA[agreement]]></category>
		<category domain="http://resources.bnet.com/topic/collaboration.html"><![CDATA[collaboration]]></category>
		<category domain="http://resources.bnet.com/topic/merck+%2526+co.+inc..html"><![CDATA[Merck & Co. Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/university+of+oxford.html"><![CDATA[University of Oxford]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MRK</category>
		<category domain="tickers">MRK</category>
	</item>
</channel>
</rss>
